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Abstract 
 
An experimentally determined structure for human CYP2J2, a member of the 
cytochrome P450 family with significant and diverse roles across a number of tissues, 
does not exist yet. Our understanding of how CYP2J2 accommodates its cognate 
substrates and how it might be inhibited by other ligands relies thus on our ability to 
computationally predict such interactions using modelling techniques. In this study 
we present a computational investigation of the binding of arachidonic acid (AA) to 
CYP2J2 using homology modelling, induced fit docking (IFD) and molecular 
dynamics (MD) simulations. Our study reveals a catalytically competent binding 
mode for AA that is distinct from a recently published study that followed a different 
computational pipeline. Our proposed binding mode for AA is supported by crystal 
structures of complexes of related enzymes to inhibitors and evolutionary 
conservation of a residue whose role appears essential for placing AA in the right site 
for catalysis.  
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Introduction 
Cytochrome P450s (CYPs) form a large and diverse family of monooxygenase 
enzymes involved in the metabolism of both exogenous and endogenous 
substrates[1]. CYP2J2, the only member of the CYP2J subfamily in humans, is the 
primary source of arachidonic acid (AA)-derived epoxygenase products 5,6-, 8,9-, 
11,12- and 14,15- epoxyeicosatrienoic acids (EETs) in human cardiac tissue[2].  In 
addition to the heart, the CYP2J2 mRNA is present in the liver, kidney and skeletal 
muscle, and to a lesser extent, in the small intestine, pancreas, lung and brain[3]. 
Moreover, CYP2J2 expression can be induced in endothelial cells[4] and 
monocytes[5] by bacterial  lipopolysaccharide. CYP2J2 is also expressed in a wide 
variety of tumours and tumour cell lines, where it appears to promote cell survival[6].  
CYP2J2 and the EETs it produces have been shown to regulate the inflammatory 
response, vascular tone, cellular proliferation, angiogenesis, and metabolism[3]. In 
addition to AA, CYP2J2 can also metabolise the structurally related linoleic, 
docosahexaenoic and eicosapentaenoic acids to epoxy-products with biological 
activity[7, 8]. 
In addition to the metabolism of fatty acids, similar to many CYPs, CYP2J2 
can accept a wide range of xenobiotic substrates for detoxification[9-11]. Using 
screens of marketed therapeutic agents, albendazole, amiodarone, cyclosporine A, 
danazol, mesoridazine, nabumetone, tamoxifen, thioridazine, telmisartan and 
flunarizine were all shown to be potential xenobiotic substrates for CYP2J2. 
Moreover, terfenadine[12, 13] and ebastine[13] have been used as the parent 
compounds to generate structure-based CYP2J2 inhibitors with K(i) values as low as 
160 nM[12, 13].  
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The roles of CYP2J2 in the physiology and patho-physiology of 
cardiovascular and tumour biology along with drug metabolism, have led to a quest 
for greater understanding of its structure. There is currently no crystal structure of 
CYP2J2. In the absence of an experimentally determined crystal structure, homology 
models represent an invaluable tool to progress our understanding of a protein’s 
structure-function relationship[14]. Indeed, homology models of proteins that elude 
crystallisation efforts (or have simply not yet been characterised) have contributed 
significantly to our understanding of their substrate specificity[15] and mode of 
action[16], and facilitated structure-based ligand/inhibitor design to target these 
proteins[17, 18]. 
 Homology models of CYP2J2 have been built in previous studies 
(Supplementary Table 1) using a variety of related structures as templates. Lafite et 
al.[19] used structures of CYPs 2A6, 2B4, 2C5, 2C8 and 2D6 with resolutions 
ranging from 2.05 to 3.00 Å. The templates were chosen to provide the greatest 
diversity in the family as well as in the occupancy of the active site (from no ligand to 
large ligands present). Li et al.[20] used a structure of CYP2C9 bound to warfarin as a 
template (resolution: 2.55Å). However, the template used carried significant 
mutations in the F-G region and a thorough investigation of changes to substrate 
binding was not completed prior to crystallisation[21], raising doubts about its ability 
to represent the wild type protein. Lee et al.[9] created a model based on structures for 
CYPs 2B4, 2C8, and 2A6 at an average resolution of 2.1Å and their analyses focused 
on accessibility of a variety of ligands to the active site. Cong et al.[22] created a 
model based on the 2.8Å resolution structure of CYP2R1 and concentrated on 
mutation-induced changes to AA binding based on known polymorphisms. Finally, 
more recently, Xia et al.[23] created a model based on CYP2A6, CYP2E1, 
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CYP17A1, CYP2R1 and CYP2C8 as templates (resolutions ranging from 2.2Å to 
2.8Å). The model was used to dock AA, and polymorphisms known to reduce the 
metabolism of AA were explained based on the binding mode observed in the 
docking study. 
 In the study presented here we have investigated the binding of AA to CYP2J2 
using a modelling approach that is also based on the principles of homology 
modelling and docking simulations. However, our strategy of selecting promising 
binding poses from induced fit docking and using them as starting points for 50ns-
long molecular dynamics (MD) simulations differs significantly from existing studies 
and our results are also distinct. The only two modelling studies that have examined 
the binding of AA to CYP2J2 (Xia et al.[23] and Cong et al.[22]) were partially 
carried out by the same authors and followed a very similar protocol in the building of 
their homology model. Cong et al. carried out in addition a 10ns MD simulation, but 
the main conclusions of the two studies are analogous. Both have resulted in a 
protein-ligand complex, where AA is tethered at the far end of the binding site 
channel by hydrogen bonds to Leu378 and Gly486. This model of binding relies on a 
hydrogen bond to the main chain of CYP2J2. We viewed this model with scepticism, 
as we believe that the need for specificity for AA would be better served by one or 
more residues anchoring it in place through side-chain interactions. To investigate 
further, we have built our own homology model and carried out both docking and MD 
simulations of the binding of AA to CYP2J2.  
 We present here an alternative binding mode for AA to the one that has been 
suggested in the literature. This binding mode is supported by existing crystal 
structure complexes of proteins of the same family bound to inhibitors of diverse 
structures. Differences in our model and previously suggested ones are reflected in the 
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distinct list of residues that we put forward as being important for recognition, and, 
hence, being most interesting for testing with mutagenesis experiments. In the 
absence of relevant experimental data, it is difficult to ascertain which model, if any, 
is right. Hence, we believe that until relevant experimental data become available, it is 
worth keeping in mind that binding modes distinct from the ones published so far are 
not only possible, but also plausible. 
 
Methods  
All computational modelling tasks, including protein preparation, docking and MD 
simulations were carried out using tools available in the Schrödinger molecular 
modelling software suite (www.schrodinger.com).  
 
Generation of a 3D model of CYP2J2  
The sequence of CYP2J2 was extracted from the Uniprot (www.uniprot.org) database 
entry with accession code P51589. This sequence was used to search the RCSB 
Protein Data Bank[24] (www.rcsb.org) using the ‘Search by Sequences’ facility. The 
selection of the template for the homology model was based on the following 
considerations: a) the percentage sequence identity between CYP2J2 and putative 
templates, b) the resolution of the crystal structures returned by the search, c) the 
presence and type of ligand bound in the template, and d) the completeness of the 
template protein chain (in terms of missing or mutated residues). Only proteins with 
sequence identity to the query higher than 35% were considered. Rabbit CYP2B4 
(PDB ID: 1suo[25]) was selected as the template for homology modelling based on a 
combination of relatively high sequence identity to CYP2J2 (39%), completeness of 
sequence, and high resolution of the corresponding crystal structure (1.9Å). This 
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structure (PDB ID: 1suo) has not been used in the past for the construction of a 
homology model of CYP2J2, despite the fact that it has comparable sequence identity 
and higher resolution among most structures used so far to build models. The 
sequence alignment between rabbit CYP2B4 and human CYP2J2 (Supplementary 
Figure 1) justifies the use of the first as a template for modelling the second. The 
ligand bound to CYP2B4 in the crystal structure is 4-(4-chlorophenyl)imidazole, a 
compact ligand by comparison to AA. A model based on this structure would have a 
relatively small active site that would close in further during protein preparation for 
docking, as the protein side chains would tend to move closer to one another to 
maximize interactions. To allow the active site to remain open, we carried out protein 
preparation in the presence of a larger ligand, vitamin D3 (all three ligands mentioned 
in this study are depicted in Supplementary Figure 2). This ligand was positioned in 
the CYP2J2 active site by superimposing our model with the crystal structure of 
CYP2R1 (PDB ID: 3c6g[26]), a human homologue crystallised with vitamin D3. 
Once the model CYP2J2 was optimized for docking, vitamin D3 was removed to 
leave a large, open active site ready for docking AA.   
 The template structure (PDB ID: 1suo) was prepared using the Protein 
Preparation Wizard tool[27]. Water molecules were deleted whilst the original ligand 
(CPZ) and heme molecules were retained. Prime[28] was used to generate the wild 
type homology model. The model was refined using the Protein Preparation Wizard 
and minimised using Prime Refinement. Analysis of the generated model with 
Verify3D[29] identified amino acids that were poorly modelled (Verify3D score was 
less than 0.2). These amino acids were then used as starting points for refinement 
using the Prime “refinement with proximity” approach. This protocol involves two 
cycles of minimisation: the first cycle involves amino acids proximal to the selected 
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ones (starting at 1Å) and the second involves a total minimisation of the whole 
structure. The proximity cut-off was increased by 2Å in each cycle, resulting in a total 
of 51 cycles for this protein. The minimised structures after each cycle were analysed 
with Verify3D and the best structure (in this case the result of the final cycle) was 
chosen. 
 The final model was assessed using the following structure assessment 
programs: Verify3D, ERRAT[30], PROCHECK[31], QMEAN[32]. Verify3D, 
ERRAT and PROCHECK were run on the server of the Molecular Biology Institute 
at the University of California, Los Angeles (http://services.mbi.ucla.edu). QMEAN 
score values were obtained from the QMEAN server at 
http://swissmodel.expasy.org/qmean. 
 
Generation of a complex between CYP2J2 and AA 
The 2D structure of AA was taken from the PubChem Compound[33] database and it 
was processed using Schrodinger’s LigPrep[34] tool. Ionisation states were assigned 
by Epik[35] at physiological pH (7.0). Parameters were assigned using the OPLS2005 
force field[36].  
AA was docked into the active site of the CYP2J2 model using the Induced Fit 
Docking Protocol (IFD[37]). Briefly, the first stage of this protocol scales down the 
van der Waals radii of both protein and ligand atoms by a factor of 0.5, and ligands 
are then docked into the fixed receptor using the Glide SP docking protocol. Next, 
Prime is used to predict the optimal orientation of the side chains of residues lining 
the binding site. Finally, the ligand is re-docked into the optimised binding site and 
poses are scored with Glide XP. A cubic box of 10Å3 was used for docking, centred 
on the original co-crystallised ligand in the template structure used for homology 
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modelling. Twenty top-scoring poses were kept following IFD. The poses were 
viewed and five poses were manually selected as diverse starting points for MD 
simulations. 
 
 
 
Molecular dynamics simulation of AA binding to CYP2J2 
MD simulations were carried out using the Schrödinger interface of the Desmond 
program. Five MD runs were started from the five poses selected following induced 
fit docking. The protein-ligand complex was solvated in a cube of TIP3P waters, 
extended 15Å away from any protein atom. The resulting system was then neutralised 
with the addition of sodium and chlorine ions at a concentration of 0.15M. Periodic 
boundary conditions were applied to avoid finite-size effects. Atomic partial charges 
of ligands were maintained as obtained from OPLS2005 force field. MD simulations 
were performed using Desmond v.2.4 and the OPLS2005 force field. The simulation 
protocol included starting relaxation steps and a final production phase of 50 ns at 
300K. 
In particular, the starting relaxation steps comprised an initial minimisation of 
the system over a maximum 2000 steps, with a convergence criterion of 50 
kcal/mol/Å, and the presence of harmonic restraints on the solute atoms (force 
constant = 50.0 kcal/mol/Å2); a second minimisation without restraints; a third stage 
of 12ps at 10K with harmonic restrains on the solute heavy atoms (force constant = 
50.0 kcal/mol/Å2), using NVT ensemble and Berendsen thermostat; a fourth 12 ps at 
10K, retaining the harmonic restraints, and using NPT ensemble and Berendsen 
thermostat and barostat; a fifth heating phase of 24 ps at 300 K, retaining the 
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harmonic restraints, and using NPT ensemble and Berendsen thermostat and barostat; 
a final 24 ps at 300K without harmonic restraints, using the NPT Berendsen 
thermostat and barostat. After the relaxation steps, a 50ns MD simulation was carried 
out at 300K using canonical NPT Berendsen ensemble. During MD simulations, we 
used a time step of 2 fs while constraining the bond lengths of hydrogen atoms with 
the M-SHAKE algorithm[38]. The atomic coordinates were saved every 5 ps. 
Following simulations, the Schrödinger Simulations Interaction Diagram (SID) was 
employed for analysis. SID is a post-MD analysis tool available in the Schrödinger 
environment for the easy visualisation and analysis of protein-ligand interactions 
derived from MD simulations. 
 
Preparation of figures 
Figures 1, 3, 4c, 5 have been prepared using the software Chimera[39]. Where a 
superposition of two or more structures was necessary, Chimera’s Match Maker was 
used in the global alignment mode.  
Figure 2 was prepared using output from the programs PROCHECK, QMEAN and 
ERRAT. 
Figures 4a&b, 6, 7, were prepared using the Schrödinger molecular modelling 
software. 
All additional formatting of figures and addition of labels was done using the free 
image editor Gimp (www.gimp.org).  
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Results  
 
Generation and validation of a homology model for human CYP2J2 from rabbit 
CYP2B4 
A homology model of human CYP2J2 was built using the rabbit CYP2B4 (PDB ID: 
1suo) as template. The model retained the overall fold of CYPs with 12 major helices 
and four beta sheets (Figure 1). The structural quality of the model was confirmed by 
a range of computational tools (Figure 2). The Ramachandran plot for the model 
(Figure 2a) showed good stereochemistry for over 90% of the residues (97.8% of 
residues are in “most favoured” and “additional allowed” regions, and only two of the 
463 residues modelled were in disallowed regions). Verify3D reported 93.3% of 
residues as having an average 3D-1D score >=0.2. The calculated QMEAN score for 
this model was 0.77, and the associated Z-score was -0.03. The QMEAN score is an 
estimate of the “degree of nativeness” of the structural features in the model, and, as 
shown in Figures 2b&c, this model displayed “native-like” features, when compared 
with a high quality reference dataset of structures. ERRAT, which uses statistics of 
non-bonded interactions in the model and compares them to those of high quality 
crystal structures, produced an overall quality factor of 77.1%, meaning that 77.1% of 
all residues had calculated error values below the 95% rejection limit (Figure 2d). All 
these quality metrics are comparable with those reported in publications of existing 
models of CYP2J2. In addition, our model was compared to those listed in 
ModBase[40] as well as others built automatically by the Protein Model Portal[41] 
(Supplementary Table 2). The results show our model to be of comparable, or 
superior quality (not unexpectedly, given the automated nature of these model 
builders). Furthermore, the models listed in Supplementary Table 2 lack the heme 
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moiety whilst our method preserves the co-factor in the final model. Co-factor 
exclusion or incorrect placement is a major drawback of using automated modelling 
servers, currently only circumvented by manual inclusion. 
 
 
Finally, the active site volume of our model was calculated to be 234Å3 using the 
SiteMap[42] method. This value is similar to the volumes found by Xia et al.[23] 
(330Å3) and Cong et al.[22] (320Å3) but notably smaller than those reported by Lafite 
et al.[19] (945Å3) and Lee et al.[9] (1420Å3). There are several potential reasons for 
this discrepancy. The models may differ significantly in their conformation, but we 
cannot ascertain this, as we have no access to these models and there are no 
coordinates deposited in a public repository. However, other more technical reasons 
may also be responsible for the differences observed. Programs differ widely in their 
definition of a “cavity” and the corresponding calculation of its volume. For example, 
the inclusion or exclusion of a solvent accessible channel leading to the heme whilst 
calculating the volume of the binding site could justify the differences between the 
reported values in the literature. In addition, the inclusion of heme itself could alter 
the results significantly due to the large volume occupied by this cofactor. Indeed, 
calculations of the active site volume using fpocket[43] or the cavities analysis from 
the PDBsum[44] server (http://www.ebi.ac.uk/thornton-
srv/databases/pdbsum/Generate.html) give much larger estimates for our model 
(1339Å3 and 1977Å3 respectively), but it is clear from Supplementary Figure 3 that 
this is due to merging of cavities that are forming a channel towards the heme. 
Moreover, we show in Supplementary Figure 3 that a comparison of the active site 
volumes of different models may be less relevant, given that the movement of side 
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chains during the MD run allows the sampling of conformations with considerable 
variation in the active site volume, at least as perceived by software.  
 
 
Induced fit docking suggests that AA is tethered to the CYP2J2 active site by a 
hydrogen bond to Arg117 
Following preparation of both the small molecule ligand and the protein, AA was 
docked into the active site of the CYP2J2 model using a flexible receptor protocol 
(Induced Fit Docking or IFD[37], as described in the Methods). The twenty resulting 
poses of AA following the IFD protocol are depicted (superimposed) in Figure 3. In 
contrast to previously identified poses involving a hydrogen bond to the main chain 
atoms of Leu378, all our IFD poses showed the AA carboxylic group facing away 
from Leu378, and interacting with Arg117 instead.  Hydrogen bonds to both side and 
main chain atoms of Arg117 were observed for the top ranking poses (Figure 3b) but 
there was small variation in the positioning of the carboxylic acid among the lower-
ranking of the 20 IFD poses, leading to slightly different interaction profiles with the 
protein (see examples of protein-ligand interaction diagrams in Supplementary Figure 
4). A hydrogen bond to the Arg117 side-chain was observed in 19 cases (the 20th only 
just failing the cut-off for the minimum acceptor angle), and in 11 of the 20 poses the 
Arg117 backbone was also involved in a hydrogen bond with AA. Hence, Arg117 
plays a major role in stabilizing the observed AA poses. Moreover, Met116 appeared 
to be playing a supportive role in the recognition of AA, as in just under half the poses 
(8 of 20), the Met116 backbone was also hydrogen-bonded to the AA carboxylate tail. 
In addition to the residues mentioned above, a channel to the active site was lined by a 
network of mostly hydrophobic residues, creating a favourable environment for the 
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long non-polar AA chain. The following ten residues were in contact with the 
substrate in all 20 poses from IFD: Thr114, Phe121, Ile127, Asp307, Phe310, Ala311, 
Glu314, Thr315, Ile376 and Ile487, while there were several others that appeared in at 
least half the poses (e.g. Pro115, Ile120, Val218, Glu222, Trp251). 
 
 
 
Molecular dynamics simulations of AA bound to CYP2J2 confirm the 
importance of Arg117 as a tether for the substrate 
Five MD simulations were run (two for 30 ns and three for 50 ns) starting with five 
manually selected and diverse poses from the IFD runs. Here we concentrate on the 
analysis of one of the 50 ns runs (referred to here as run 2), which resulted in the most 
promising (from a catalysis point of view) and most stable (especially during the last 
nanoseconds of the simulation) position for the binding of AA to CYP2J2. We 
occasionally refer to the remaining MD runs in this section, where we believe it is 
instructive to do so. 
 The conformation of the protein did not change drastically during the 
simulation (Figure 4a). Although an increase in the average RMSD values for the 
protein C-alpha atoms was observed around the 35th ns of the simulation, the RMSD 
values stayed within the 3Å range, and so were within what might be expected from 
thermal fluctuations of a small globular protein. Amino acids with the largest 
fluctuations during the simulation are highlighted in the Root Mean Square 
Fluctuation (RMSF) plot (Figure 4b) and map to highly flexible loops on the protein 
structure (Figure 4c), confirming that the increase in the average RMSD was not due 
to major restructuring of parts of the protein, but to expected fluctuations of flexible 
loops on the surface. By contrast, amino acids involved in the binding of the ligand 
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appeared stable during the simulation and exhibited, as expected, the lowest 
fluctuations (Figure 4b). AA displayed a similar stability throughout the simulation, 
indicative of a narrow binding site that allows only restrained conformational 
movements (Figure 4a). 
In the final frame of the 50ns simulation, AA was positioned in a catalytically 
competent orientation within the small hydrophobic tunnel on top of the heme 
molecule (Figure 5a). Comparison with the final frames from the remaining 4 
simulations (Supplementary Figure 5a) highlight a number of ligand-binding poses 
that potentially represent AA on the route to approaching the heme. Ligand-only 
RMSD values between the AA atoms of these four last frame snapshots and the AA 
atoms of the last frame of run 2 vary from 3.4 to 9.3Å. In run 2 the ω9 double bond 
positioned above the iron at a distance of approximately 3.5Å in a plane parallel to the 
heme  (Figure 5b&c). This distance fluctuated between 3 and 4.5Å throughout most 
of the simulation (Figure 6a), a range consistent with distances previously described 
for a heme-catalysed epoxidation reaction[45]. Literature data on the regioselectivity 
of this enzyme indicates epoxidation rates of 37% for ω6 vs 18% for ω9[3]. Although 
this suggests a small preference for the ω6 bond, our simulation was not sensitive 
enough to reproduce this result. However, we did observe ω6 approaching the iron 
atom at around 30 ns, as is evident from the distance plot in Figure 6b. ω9 showed the 
opposite profile, with its distance to iron increasing significantly in the same 
timeframe (Figure 6a). Finally, we also monitored the ω6 and ω9 distances from iron 
for two of the remaining four simulations (runs 3 and 7; the other two stay too far 
from the heme for this distance to be meaningful). During both these simulations there 
are time slots when ω9 is at a reasonable distance (between 3 and 4Å) from the iron 
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atom but for most of the time the distances are longer than 4.5Å and so unlikely to 
represent poses representative of a catalytic event (Supplementary Figure 5b). 
The interaction of protein residues with AA during the 50ns of the simulation 
are summarised in Figure 7. A number of hydrophobic residues that line the binding 
site stabilise the ligand in place (Phe310, Ile127, Ala311, Ile375, Ile376 and others). 
As the simulation progresses and the complex equilibrates, these interactions become 
stronger (at about 25 ns) and the ligand appears to stabilise further (Figure 4a). 
Similarly to what was seen in the induced-fit docking poses, Arg117, Met116 and 
Thr114 are involved in hydrogen bonds to the small molecule substrate, anchoring it 
in place. The most persistent hydrogen bonds between AA and CYP2J2 were formed 
by Arg117 (53.8% and 44.4% of the simulation time the main-chain and side-chain 
nitrogens respectively were involved in a hydrogen bond to the ligand). Thr114 was 
involved in an equally persistent hydrogen bond through its side-chain (43.4% of the 
time), whereas the hydrogen bond to the Met116 main chain nitrogen was observed 
less than half of that time (17.7%) in this simulation.  In the other two MD runs where 
the ligand approached the heme (runs 3 and 7), hydrogen bonds were again observed 
predominantly to Arg117, with one simulation (run 3) showing persistent hydrogen 
bonds to the main chain (76.2%) whereas the other (run7) showed interactions with 
the side-chain nitrogens (50.7% and 19.9%). Hydrogen bonds to the main-chain of 
Met116 were only persistent in run 3 (46.2%) and almost absent in run 7 (4.6%), 
whereas interactions with the Thr114 side chain were present in both runs for 
significant periods of time (run3: 25.3%; run7: 29.9%).  
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Discussion 
In this study we present an investigation into the binding of AA to CYP2J2 based on a 
homology model of the enzyme structure, induced fit docking of AA to the enzyme 
and a 50ns MD simulation that starts from realistic poses identified at the IFD stage. 
Our model structure of CYP2J2 is of high quality, as assessed by several tools 
(Verify3D, ERRAT, PROCHECK, and QMEAN).  The core of the structure, and 
importantly, the access channel, is similar to the ones reported in recent 
studies[19],[23],[46] and lined in each case by the same hydrophobic residues (or a 
subset thereof). The convergence of models to the same core structure with a common 
access channel increases our confidence in our model. Where our model differs 
significantly from the pose suggested by Cong et al[22] is in the suggested mode of 
recognition of the substrate AA. The difference appears to originate at least partially 
by the assignment of a protonated state to the AA carboxylate group. The pKa of AA 
is 4.82 (http://www.drugbank.ca/drugs/DB04557) making it likely to be mostly 
unprotonated at physiological pH. In our study, AA is unprotonated and hence able to 
take advantage of the strong hydrogen bonding capabilities of Arg117. Further 
evidence supporting the validity of our model is presented below. 
A number of crystal structures of complexes of CYP2 with inhibitors support 
the binding mode for AA suggested by our study. In the structure of the inhibitor 
troglitazone bound to human CYP2C8 (PDB ID: 2vn0[47]), the inhibitor’s position 
overlaps with the region occupied by the carboxylic acid of AA and interacts with 
Ser103, the residue corresponding to Arg117 in the sequence alignment of the two 
enzymes (Supplementary Figure 6a). In the same structure, Thr364, which 
corresponds to Leu378 in CYP2J2, shows no interactions with the co-crystallised 
inhibitor. Other ligands in complex with related cytochrome P450s also appear to bind 
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closer to residues equivalent to Arg117 than to residues equivalent to Leu378 (e.g. 
abiraterone bound to CYP17A1 (PDB ID: 3ruk[48]), vitamin D3 bound to CYP2R1 
(PDB ID: 3c6g[49]), or bifonazole bound to CYP2B4 (PDB ID: 2bdm[50]) – see 
Supplementary Figure 6b). There are, of course, crystal structures of CYP450s with 
inhibitors bound in different sites. Notably, the second bifonazole molecule bound to 
CYP2B4 is positioned closer to the Leu378 side of the pocket but further away from 
the heme moiety, and so likely represents a less catalytically relevant pose of the 
ligand. Similarly, warfarin bound to CYP2C9 (PDB ID: 1og5[51]) is positioned closer 
to Thr364 (the residue equivalent to Leu378) than to the Arg117 equivalent. However, 
warfarin is a bulky ligand with a very different shape to the flexible AA, and so 
differences between its binding and that of AA’s are not surprising. 
Several docking studies further support our model. Lafite et al.[19] used their 
CYP2J2 model for docking the inhibitor terfenadone and its derivatives and found 
that the keto group of terfenadone is held in place through hydrogen bonding 
interactions with the guanidine moiety of Arg117. Additionally, the hydrophobic part 
of terfenadone was accommodated in the narrow tunnel leading to the heme through a 
series of contacts to the same residues that we have identified as important in holding 
the hydrophobic part of AA. In the same study, three derivatives of terfenadone 
presented a similar interaction profile with CYP2J2. Likewise, Li et al.[20] used a 
CYP2J2 model for docking studies of four ligands sharing the same scaffold: 
ebastine, terfenadine, terfenadone and a terfenadone derivative. Arg117 formed a 
hydrogen bond to ebastine and, although it did not hydrogen bond to the other three 
ligands, it was listed as one of the residues contributing significant amounts of energy 
to the interaction. Similarly, in the Ren et al.[46] study (where the Li et al. homology 
model was used), inhibitors telmisartan and flunarizine bind in a pocket that includes 
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Arg117, and the orientation of telmisartan’s carboxylic group after 2 ns of MD 
simulations suggests that a longer simulation might include poses that hydrogen bond 
to Arg117. Interestingly, telmisartan binds far from the heme group, yet it is a potent 
inhibitor of CYP2J2. In our model, blocking access of the substrate to Arg117 leads to 
the loss of an important hydrogen bond, which should make it easier for a ligand to 
compete for binding the enzyme. 
 Finally, a model where AA interacts with Arg117 is supported by evolutionary 
conservation of this residue. In the absence of a manually curated dataset of CYP2J2 
enzymes from other organisms, we obtained an alignment of all members of the same 
protein family from Ensembl (protein family ID: PTHR24300_SF91). This is a 
broadly defined family with members that share the same Enzyme Commission 
number (E.C. 1.14.14.1) but not necessarily the same substrates. Examining the 
family sequence alignment, it appears at first that Arg117 is conserved in this family 
(61.8% conservation within a group of 165 proteins) but to a lesser extent than 
Leu378, which shows 80% conservation. However, on closer inspection, the majority 
of sequences with a residue other than arginine at this position either have much 
shorter sequences and are thus unlikely to have the same function, or they originate 
from Uniprot/TrEMBL entries where functional annotation is either not present or 
assigned by sequence similarity only. Removing these sequences that are unlikely to 
be true orthologues, leaves a group of 64 sequences where arginine is prevalent (68% 
conserved) but glutamine is also common at this position. Restricting the selection 
further to 15 sequences that both carry the label CYP2J2 in Ensembl and share at least 
70% sequence identity at the gene level (both for the target and the query sequences), 
reveals that Arg117 is conserved in all but one sequence (where it is replaced by 
glutamine – see Supplementary Figure 7). Although it is hard to speculate about the 
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significance of these findings, given the overall high sequence identities shared by 
these protein homologues, there appears to be some evolutionary pressure for 
conserving a good hydrogen bond donor at this position. Perhaps more interesting are 
the results of comparing CYP2J2 with its rat homologue CYP2J3, which shares 
73.9% sequence identity with the human enzyme (see alignment in Supplementary 
Figure 8). CYP2J3, like CYP2J2, metabolises AA to EETs[52]. In both CYP2J2 and 
CYP2J3, Arg117 and the amino acids of the narrow hydrophobic tunnel to the heme, 
are conserved. In the rat enzyme, Met116 is substituted by a leucine, a very 
conservative substitution. In contrast, Leu378 and Gly486, the two residues suggested 
in the previous study[22] as interacting with AA are replaced in CYP2J3 by 
phenylalanine and serine respectively, despite the very high conservation of the two 
enzyme sequences. Although the Cong et al. model predicts an interaction of AA with 
the backbone of Leu378 and Gly486, which would lessen the impact of mutations in 
the sequence, conservation of Arg117 in a homologue known to bind AA is consistent 
with an important functional role for this residue. 
 
 
Conclusions 
Our homology model of CYP2J2, in combination with IFD calculations and 50 ns 
MD simulations have led us to suggest a new binding mode for AA, that differs 
significantly from the recent suggestions in the literature. The main difference in our 
model is the residue employed to anchor the hydrophilic tail of AA in place (primarily 
Arg117). The support for our results is two-pronged: first, the similarity of our 
proposed binding mode to that of the binding of inhibitors CYP2J2 in the literature; 
and second, the conservation of Arg117 and conservative substitution of Met116 in an 
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enzyme in rat that performs the same reaction. Until relevant experimental data 
become available, we believe it is worth keeping in mind this alternative mode of 
binding, especially when designing mutagenesis experiments. 
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Figure Captions 
 
Fig. 1 Homology model of human CYP2J2 
a & b. Ribbon representation of front (a) and back (b) views of the human CYP2J2 
model. The 12 major helices are coloured in the rainbow depiction shown in Figure 1 
of Cong et al.[22] The rest of the structure is shown in grey. 
c. Superposition of the crystal structure of the template structure (rabbit CYP2B4; 
PDB ID: 1suo; grey) onto the homology model of human CYP2J2 (orange).  
 
 
Fig. 2 Quality assessment of our CYP2J2 homology model 
Assessment of our CYP2J2 homology model by PROCHECK (A), QMEAN (B&C) 
and ERRAT (D). 
a. A Ramachandran plot confirms good stereochemical quality of our model of 
CYP2J2. Results from PROCHECK: residues in most favoured regions: 81.1%; 
residues in additional allowed regions: 16.7%; residues in generously allowed 
regions: 1.7%; residues in disallowed regions: 0.5%. 
b. The QMEAN score of our model shown in red against the background of scores of 
high quality crystal structures of similar size. The calculated Z-score of -0.03 
confirms a good degree of “nativeness” of structural features in our model. 
c. Density plot of QMEAN scores for all reference models used in the calculation of 
the Z-score in plot (b). The score for our model is shown by the red line on the plot. 
d. ERRAT plots of the error values associated with each residue in the homology 
model. 
 
 
Fig. 3 Induced fit docking of arachidonic acid to CYP2J2 suggests a binding 
mode anchored primarily by a hydrogen bond to Arg117 
 
a. Superposition of 20 poses from IFD of AA to CYP2J2 show AA positioned to 
hydrogen bond to the Arg117 side-chain, and away from Leu378. All 20 poses are 
superimposed on the heme cofactor (only one copy of heme is shown), with AA 
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depicted in dark grey wireframe, and heme and the protein residues Arg117 and 
Leu378 depicted as sticks.  
b. Top-ranking pose from IFD (Glide GScore -11.2 kcal/mol) depicts AA anchored in 
its place by hydrogen bonds to both the side-chain and main-chain nitrogens of 
Arg117. AA is depicted in stick mode (only heavy atoms shown), whereas Arg117 is 
shown in an all-atom representation. Hydrogen bonds are shown as cyan lines.  
c. Six of the twenty IFD poses with the most diverse positions for the AA carboxylic 
acid are depicted in this figure. Only AA and the heme molecule from these six poses 
are shown. 
 
 
Fig. 4 Protein and ligand molecules remain relatively stable during 50ns of MD 
simulation 
a. Time-dependent root mean square deviation (RMSD) of the protein C-alpha 
carbons (blue) and ligand (purple) atoms during the time of the MD simulation. The 
first frame is used as the reference for calculating RMSD values. The ligand RMSD is 
measured for the ligand heavy atoms after superimposing the protein-ligand complex 
on the protein backbone of the reference structure. Thus, the ligand RMSD in this 
case reflects how stable the ligand is with respect to the protein and its binding site. 
b. Residue-specific root mean square fluctuations (RMSF) during the trajectory of the 
MD simulation. Highest-fluctuating residues are labelled on the plot. The original 
numbering of the residues can be obtained by adding 39 to the numbers on the x-axis. 
The labels on the peaks correspond to correct (canonical) labelling of CYP2J2. 
c. Superposition of 10 structures extracted every one nanosecond from the period 35-
45 ns of the MD simulation.  Highly flexible residues (labelled and highlighted in 
orange) are, as expected, all in loops facing the solvent and away from the heme 
(sticks coloured by heteroatom) and arachidonic acid (blue sticks) in the middle of the 
enzyme. 
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Fig. 5 AA adopts a catalytically competent position above the heme group during 
the MD simulation 
 
a. A primarily hydrophobic tunnel accommodates AA in a catalytically competent 
position above heme (only the last frame of the MD simulation is shown here). 
Protein residues shown are within 3Å of any atom of AA (shown as yellow sticks). 
The protein residues are coloured by a hydrophobic scale that ranges from red (very 
hydrophobic) to blue (very hydrophilic). 
b. & c. Side (b) and top (c) views of the CYP2J2–AA complex, as seen in the last 
frame of the 50ns MD simulation. Distances from the heme iron to the carbon atoms 
of the ω9 double bond are shown in (b). 
 
 
 
Fig. 6 The ω9 and ω6 bonds of AA are swapping positions during the MD 
simulation confirming the possibility of epoxidation at both bonds 
 
The distance between the heme iron and either the ω9 (a) or ω6 (b) bonds of AA are 
plotted against the time of the simulation. Whilst most of the time we observe ω9 at a 
distance ready for catalysis, at approximately 30ns the ligand flips and ω6 becomes 
the bond approaching the heme in a catalytically competent distance.  
  
 
Fig. 7 Protein-ligand contacts during the 50ns simulation 
a. Hydrogen bonds (green) and hydrophobic interactions (purple) between protein and 
ligand atoms are monitored during the MD simulation and summarised in this plot. 
The height of the bars indicates the time that a given protein residue spends being 
involved in a type of interaction with the ligand. Met316, for example, is associated 
with a bar of approximate height 1, indicating that it is involved in a hydrogen bond 
across the full trajectory. Heights greater than 1 (such as the one seen for Arg117) are 
due to multiple contacts of the same type and of the same protein residue with a 
ligand molecule. 
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b. Protein-ligand contacts are monitored across the time of the simulation. Contacts 
by specific protein residues per frame of the trajectory are depicted in the bottom part 
with orange lines indicating a contact and a darker shade of orange indicating more 
than one contact per residue. The total number of contacts for all protein residues is 
monitored in the top panel (blue lines). Arg117, Thr114 and Met116 stand out as the 
residues with the highest number of contacts across the time of the simulation. 
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